[1-(Cyclopropylmethyl)cyclobutyl]methanol | 433219-80-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [1-(Cyclopropylmethyl)cyclobutyl]methanol
• 英文别名: [1-(cyclopropylmethyl)cyclobutyl]methanol
• CAS: 433219-80-8
• 化学式: C₉H₁₆O
• 分子量: 140.225
• InChiKey: MKEZIQZDWDINDV-UHFFFAOYSA-N

物化性质

• 沸点：
  195.6±8.0 °C(Predicted)
• 密度：
  1.039±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  [1-(Cyclopropylmethyl)cyclobutyl]methanol 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 1-(Cyclopropylmethyl)cyclobutanecarbaldehyde
  参考文献：
  名称：

  Development of a highly selective EP2-receptor agonist. Part 1: identification of 16-hydroxy-17,17-trimethylene PGE2 derivatives

  摘要：

  Design and synthesis of an EP2-receptor selective agonist began with the chemical modification of alpha- and omega-chains of butaprost 1a, which exhibits an affinity for the IP-receptor. Two series of prostaglandin (PG) analogues with a 16-hydroxy-17,17-trimethylene moiety as an omega-chain were identified. Among those tested, 4a,b,e,f,h and 6a,b,e,f,h were found to be highly selective EP2-receptor agonists. Structure activity relationships are discussed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00369-8
• 作为产物：
  描述：

  环丁基甲酸 在 lithium aluminium tetrahydride 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 15.5h， 生成 [1-(Cyclopropylmethyl)cyclobutyl]methanol
  参考文献：
  名称：

  Development of a highly selective EP2-receptor agonist. Part 1: identification of 16-hydroxy-17,17-trimethylene PGE2 derivatives

  摘要：

  Design and synthesis of an EP2-receptor selective agonist began with the chemical modification of alpha- and omega-chains of butaprost 1a, which exhibits an affinity for the IP-receptor. Two series of prostaglandin (PG) analogues with a 16-hydroxy-17,17-trimethylene moiety as an omega-chain were identified. Among those tested, 4a,b,e,f,h and 6a,b,e,f,h were found to be highly selective EP2-receptor agonists. Structure activity relationships are discussed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00369-8

文献信息

• [EN] PYRAZOLIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS<br/>[FR] COMPOSES DE PYRAZOLIDINONE UTILISES COMME LIGANDS DES RECEPTEURS EP2 ET/OU EP4 AUX PROSTAGLANDINES
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2003035064A1

  公开（公告）日：2003-05-01

  The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.

  本发明提供了取代吡唑烷酮化合物，以及利用或包含一个或多个这样的化合物的治疗方法和制药组合物。本发明的化合物可用于多种治疗，包括治疗或预防早产、痛经、哮喘、高血压、不孕或生育障碍、不良血液凝块、先兆子痫或子痫、嗜酸性粒细胞障碍、性功能障碍、骨质疏松症和其他破坏性骨疾病或障碍，以及与前列腺素EP2和/或EP4受体相关的其他疾病和障碍。
• Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
  申请人：——

  公开号：US20040254233A1

  公开（公告）日：2004-12-16

  The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.

  本发明提供了取代吡唑啉酮化合物，以及利用或包含一个或多个这样的化合物的治疗方法和制药组合物。本发明的化合物对于各种疗法都有用，包括治疗或预防早产、痛经、哮喘、高血压、不孕或生育障碍、不良血栓形成、先兆子痫或子痫、嗜酸性粒细胞异常、性功能障碍、骨质疏松症和其他破坏性骨疾病或疾病，以及与前列腺素EP2和/或EP4受体相关的其他疾病和疾病。
• Pyrrolidine derivatives as prostaglandin modulators
  申请人：Liao Yihua

  公开号：US20050176800A1

  公开（公告）日：2005-08-11

  Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin family of compounds. In a preferred aspect, a substituted pyrrolidine compound is administered to a subject in coordination with a phosphodiesterase inhibitor compound.

  本发明提供了替代吡咯烷化合物，并提供了利用或包含一种或多种这样的化合物的治疗方法和制药组合物。本发明的化合物可用于多种疗法，包括治疗或预防早产、痛经、哮喘、高血压、不孕症或生育障碍、不良血凝、先兆子痫或子痫前期、嗜酸性粒细胞异常、性功能障碍、骨质疏松和其他破坏性骨疾病或疾病，以及与前列腺素家族化合物相关的其他疾病和疾病。在优选方面，替代吡咯烷化合物与磷酸二酯酶抑制剂化合物协同给予病人。
• PYRAZALIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS
  申请人：ARALDI Gian Luca

  公开号：US20080234346A1

  公开（公告）日：2008-09-25

  The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.

  本发明提供了取代吡唑烷酮化合物，以及利用或包含一种或多种这样的化合物的治疗方法和药物组合物。本发明的化合物可用于多种治疗，包括治疗或预防早产、痛经、哮喘、高血压、不孕或生育障碍、不良血凝、先兆子痫或子痫、嗜酸性粒细胞异常、性功能障碍、骨质疏松症和其他与前列腺素EP2和/或EP4受体相关的疾病和障碍。
• PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS
  申请人：LIAO Yihua

  公开号：US20080114051A1

  公开（公告）日：2008-05-15

  Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteoporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin family of compounds. In a preferred aspect, a substituted pyrrolidine compound is administered to a subject in coordination with a phosphodiesterase inhibitor compound.

  本发明提供了取代吡咯烷化合物，以及利用或包含一种或多种这样的化合物的治疗方法和制药组合物。本发明的化合物可用于各种疗法，包括治疗或预防早产、痛经、哮喘、高血压、不孕症或生育障碍、不良血凝、妊娠高血压综合症或子痫前期、嗜酸性粒细胞异常、性功能障碍、骨质疏松症和其他破坏性骨疾病或障碍，以及与前列腺素家族化合物相关的其他疾病和障碍。在首选方面，取代吡咯烷化合物与磷酸二酯酶抑制剂化合物协同给予给受试者。